Encorium and Protherics sign $1.6 million contract

Encorium will be utilizing its internal resources in Europe and North America to assist Protherics with program consulting, project management, site management and monitoring, data management, oversight of the data monitoring committee, and end-of-study medical report writing. Encorium has been working with Protherics since the end of 2007 in designing and writing the protocol for the forthcoming study.

Kai Lindevall, CEO of Encorium, said: “The current contract gives Encorium the opportunity to work with a new client on the development of an exciting and innovative immunotherapeutic agent that lies at the interface between two of our greatest therapeutic area of strengths – cardiovascular disease and vaccines. This contract is the second in a series of new business awards that our company expects to announce over the next several weeks.”